Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, ant… Read more
Kilitch Drugs (India) Limited (KILITCH) - Total Liabilities
Latest total liabilities as of September 2025: ₹1.34 Billion INR
Based on the latest financial reports, Kilitch Drugs (India) Limited (KILITCH) has total liabilities worth ₹1.34 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kilitch Drugs (India) Limited - Total Liabilities Trend (2006–2025)
This chart illustrates how Kilitch Drugs (India) Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kilitch Drugs (India) Limited Competitors by Total Liabilities
The table below lists competitors of Kilitch Drugs (India) Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kwang Myung El
KO:017040
|
Korea | ₩88.81 Billion |
|
P5X0
F:P5X0
|
Germany | €1.36 Million |
|
Hotel Holiday Garden
TW:2702
|
Taiwan | NT$3.37 Billion |
|
ASTech Co., Ltd.
KQ:453860
|
Korea | ₩39.89 Billion |
|
Capital Properties Inc
OTCQX:CPTP
|
USA | $1.16 Million |
|
Western Capital Resources Inc
OTCQB:WCRS
|
USA | $39.81 Million |
|
RESAAS Services Inc
OTCQB:RSASF
|
USA | $998.22K |
Liability Composition Analysis (2006–2025)
This chart breaks down Kilitch Drugs (India) Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.40 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kilitch Drugs (India) Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kilitch Drugs (India) Limited (2006–2025)
The table below shows the annual total liabilities of Kilitch Drugs (India) Limited from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹1.12 Billion | +74.45% |
| 2024-03-31 | ₹643.88 Million | -6.60% |
| 2023-03-31 | ₹689.41 Million | -0.88% |
| 2022-03-31 | ₹695.55 Million | -5.62% |
| 2021-03-31 | ₹736.97 Million | +229.59% |
| 2020-03-31 | ₹223.60 Million | +9.03% |
| 2019-03-31 | ₹205.07 Million | +37.49% |
| 2018-03-31 | ₹149.16 Million | +27.56% |
| 2017-03-31 | ₹116.93 Million | +46.30% |
| 2016-03-31 | ₹79.93 Million | +16.62% |
| 2015-03-31 | ₹68.54 Million | -22.47% |
| 2014-03-31 | ₹88.41 Million | -50.37% |
| 2013-03-31 | ₹178.13 Million | -70.94% |
| 2012-03-31 | ₹612.90 Million | -18.67% |
| 2011-03-31 | ₹753.59 Million | +17.44% |
| 2010-03-31 | ₹641.68 Million | -18.13% |
| 2009-03-31 | ₹783.76 Million | -2.24% |
| 2008-03-31 | ₹801.74 Million | +41.26% |
| 2007-03-31 | ₹567.56 Million | +74.10% |
| 2006-03-31 | ₹326.00 Million | -- |